학술논문

Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study
Document Type
article
Source
Cancer Medicine. 12(4)
Subject
Paediatrics
Biomedical and Clinical Sciences
Neurosciences
Clinical Research
Pediatric
Rare Diseases
Behavioral and Social Science
Cancer
Humans
Young Adult
Adolescent
Adult
Brain-Derived Neurotrophic Factor
Longitudinal Studies
Quality of Life
Cohort Studies
Cognitive Dysfunction
Neoplasms
adolescent and young adult
brain-derived neurotrophic factor
cancer
cancer-related cognitive impairment
cognition
inflammatory cytokines
Biochemistry and Cell Biology
Oncology and Carcinogenesis
Oncology and carcinogenesis
Language
Abstract
BackgroundThere is little information about cancer-related cognitive impairment (CRCI) in adolescent and young adults (AYA, 15-39 years old) due to its rare incidence. Here, we present the pre-treatment (before chemotherapy or radiotherapy) evaluation of cognitive function and ability of AYA with cancer (AYAC) in a multicentered cohort study.MethodsNewly diagnosed AYAC and age-matched healthy controls (HC) were recruited between 2018 and 2021. The primary outcome was the comparison of pre-treatment cognitive impairment defined as 2 standard deviations (SDs) below the HC on ≥1 cognitive test, or >1.5 SDs below on ≥2 tests using CANTAB® between AYAC and HC. Secondary outcomes included self-perceived cognitive ability assessed by FACT-Cog v3 and biomarkers (inflammatory cytokines and brain-derived neurotrophic factor [BDNF]).ResultsWe recruited 74 AYAC (median age = 34) and 118 HC (median age = 32). On objective cognitive testing, we observed three times more AYAC patients performed poorly on at least 2 cognitive tests compared to HC (40.5% vs. 13.6%, p